The permission granted by DCGI in August was for a three-dose schedule, which was tested for efficacy in the Phase 3 clinical trials.
Further, a decision on whether all children or only those with co-morbidities will be administered the COVID-19 vaccine on priority has not yet been taken, the government said on Thursday.
Sharvil Patel said Zydus Cadila is actively looking at ramping up manufacturing both domestically through partnerships and also outside of the country.
ZyCoV-D has received approval for emergency use authorisation from the Drug Controller General of India and it will be administered to people 12 years and above.
This is the world's first DNA-based vaccine against the coronavirus, and this three-dose vaccine when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response.
Zydus Cadila last month had said that it has applied for emergency use authorisation (EUA) with the Indian Drug regulator for its three-dose COVID-19 vaccine ZyCoV-D.
In its submission, the company claimed that in the interim analysis, based on 90 confirmed Covid-19 cases, no moderate, severe disease or deaths were reported in those vaccinated with ZyCoV-D.
There are children among the 23 crore Indians who have been pushed into poverty and will never return to class. Prolonged school closures have reversed decades of gains in education
ZyCoV-D, has been sent by pharmaceutical firm Zydus Cadila for emergency use authorisation to the DGCI after its clinical trials ended successfully in the country.
None of the children who underwent the clinical trials are having any side effects or other health complications two months after the vaccines were administered to them, said Dr Amit Bhate
If the regulatory approvals come through, the vaccine, being called ZyCoV-D now, will be the first DNA vaccine, licensed for use in humans.